7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases

被引：70

作者：

Boschelli, DH ^{[1
]}

Wang, YND ^{[1
]}

Johnson, S ^{[1
]}

Wu, BQ ^{[1
]}

Ye, F ^{[1
]}

Sosa, ACB ^{[1
]}

Golas, JM ^{[1
]}

Boschelli, F ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Pearl River, NY 10965 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 07期

关键词：

D O I：

10.1021/jm0499458

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We previously reported that several 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles were potent inhibitors of Src kinase activity. We disclose here a new highly efficient and versatile route to these compounds, which are also potent inhibitors of Abl kinase.

引用

收藏

页码：1599 / 1601

页数：3

相关论文

共 33 条

[1] Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity [J].

Boschelli, DH ;

Ye, F ;

Wang, YD ;

Dutia, M ;

Johnson, SL ;

Wu, BQ ;

Miller, K ;

Powell, DW ;

Yaczko, D ;

Young, M ;

Tischler, M ;

Arndt, K ;

Discafani, C ;

Etienne, C ;

Gibbons, J ;

Grod, J ;

Lucas, J ;

Weber, JM ;

Boschelli, F .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) :3965-3977

[2] Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity [J].

Boschelli, DH ;

Fe, Y ;

Wu, BQ ;

Wang, YD ;

Sosa, ACB ;

Yaczko, D ;

Powell, D ;

Golas, JM ;

Lucas, J ;

Boschelli, F .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (21) :3797-3800

[3] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[4] Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [J].

Corbin, AS ;

Buchdunger, E ;

Pascal, F ;

Druker, BJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32214-32219

[5] Role of Src in signal transduction pathways [J].

Courtneidge, SA .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 :11-17

[6]

Dorsey JF, 2000, CANCER RES, V60, P3127

[7] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia [J].

Druker, BJ ;

Lydon, NB .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :3-7

[8] Src in cancer: deregulation and consequences for cell behaviour [J].

Frame, MC .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (02) :114-130

[9]

Golas JM, 2003, CANCER RES, V63, P375

[10] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

← 1 2 3 4 →